17. Multiple system atrophy Clinical trials / Disease details
Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04165486 (ClinicalTrials.gov) | July 21, 2022 | 14/11/2019 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy | Multiple System Atrophy | Drug: ION464;Drug: Placebo | Ionis Pharmaceuticals, Inc. | NULL | Recruiting | 40 Years | 70 Years | All | 40 | Phase 1 | Austria;France;Germany;United Kingdom;Portugal |